Alembic Aims To Build On Booming US Business
Launches Let US Sales Leap By 61%
With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.
You may also be interested in...
Reporting positive fourth-quarter results at the end of its financial year, Alembic says it has achieved a milestone of its US business passing annual sales of $250m.
Alembic is building up an extensive roster of solid-dose, ophthalmic and dermatological drugs to introduce in the US. With facility clearance from the FDA, the Indian firm can now target the US market for oral solids to treat cancer.
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.